Christian Hackenberger studied chemistry in Freiburg, Madison and Aachen. After a postdoc at MIT, he started his group at FU Berlin in 2005 as an Emmy Noether fellow. In 2012, he became Leibniz-Humboldt Professor for Chemical Biology at the Leibniz-Research Institute for Molecular Pharmacology and the HU Berlin. His group develops chemical strategies to functionalize proteins and antibodies to generate protein-based pharmaceuticals against cancer, Alzheimer and viral infections. He is a co-founder of Tubulis, which engineers better tolerable cancer drugs using technologies from his lab.
The power of chemoselectivity: Functional protein-conjugates for intra- and extracellular targeting
In this presentation, l will focus on the chemical modification of functional proteins for for pharmaceutical and medicinal applications.1 In my laboratory, we use a combined approach of recently developed chemoselective reactions and enzymatic ligations, for instance the so-called P5-2 or Tub-tag3-labeling, for bioconjugation.
By generating stable antibody-drug conjugates (ADCs),2b structurally defined multivalent scaffolds4 or cell-permeable antibodies via conjugating cyclic cell-penetrating peptides,5 we provide new modalities for most challenging pharmaceutical targets, including next generation cancer therapeutics or novel inhibitors against viral infections.
Back to speaker overview Back to Oral- and Flash presentations overview